201 related articles for article (PubMed ID: 20844565)
1. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
Brown JR; Abramson J; Hochberg E; Mikler E; Dalton V; Werner L; Reynolds H; Thompson C; McDonough SM; Kuang Y; Ritz J; Neuberg D; Freedman AS
Leukemia; 2010 Nov; 24(11):1972-5. PubMed ID: 20844565
[No Abstract] [Full Text] [Related]
2. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Schulz H; Klein SK; Rehwald U; Reiser M; Hinke A; Knauf WU; Aulitzky WE; Hensel M; Herold M; Huhn D; Hallek M; Diehl V; Engert A;
Blood; 2002 Nov; 100(9):3115-20. PubMed ID: 12384407
[TBL] [Abstract][Full Text] [Related]
3. [Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
Tsukasaki K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():632-5. PubMed ID: 25831837
[No Abstract] [Full Text] [Related]
4. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
Norin S; Björkstrand B; Rommel F; Timberg L; Andersson PO; Häggström J; Aldrin A; Hansson L
Leuk Res; 2015 Jan; 39(1):33-7. PubMed ID: 25499233
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A; Steurer M; Melchardt T; Weiss L; Gassner FJ; Zaborsky N; Geisberger R; Catakovic K; Hartmann TN; Pleyer L; Voskova D; Thaler J; Lang A; Girschikofsky M; Petzer A; Greil R
Ann Hematol; 2018 Oct; 97(10):1825-1839. PubMed ID: 29862437
[TBL] [Abstract][Full Text] [Related]
8. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
9. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
10. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.
Gerrie AS; Toze CL; Ramadan KM; Li CH; Sutherland J; Yee A; Connors JM
Leuk Lymphoma; 2012 Jan; 53(1):77-82. PubMed ID: 21756026
[TBL] [Abstract][Full Text] [Related]
11. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Marchand T; Revest M; Tattevin P; Chevrier S; Poullot E; Lamy T; Houot R
Leuk Lymphoma; 2013 Mar; 54(3):643-5. PubMed ID: 22924391
[No Abstract] [Full Text] [Related]
12. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
14. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Casak SJ; Lemery SJ; Shen YL; Rothmann MD; Khandelwal A; Zhao H; Davis G; Jarral V; Keegan P; Pazdur R
Oncologist; 2011; 16(1):97-104. PubMed ID: 21212432
[TBL] [Abstract][Full Text] [Related]
15. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Gruber M; Fleiss K; Porpaczy E; Skrabs C; Hauswirth AW; Gaiger A; Vanura K; Heintel D; Shehata M; Einberger C; Thalhammer R; Fonatsch C; Jäger U
Ann Hematol; 2011 Oct; 90(10):1131-6. PubMed ID: 21617923
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
[TBL] [Abstract][Full Text] [Related]
17. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P; Villamor N; Terol MJ; González-Barca E; González M; Ferrà C; Abella E; Delgado J; García-Marco JA; González Y; Carbonell F; Ferrer S; Monzó E; Jarque I; Muntañola A; Constants M; Escoda L; Calvo X; Bobillo S; Montoro JB; Montserrat E; Bosch F
Blood; 2013 Dec; 122(24):3951-9. PubMed ID: 24124086
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
Herold T; Seiler T; Egensperger R; Trumm C; Bergmann M; Franke D; Mumm FF; Schinwald N; Buske C; Dreyling M
Leuk Lymphoma; 2012 Jan; 53(1):169-72. PubMed ID: 21812535
[No Abstract] [Full Text] [Related]
19. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
[TBL] [Abstract][Full Text] [Related]
20. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Byrd JC; Rai K; Peterson BL; Appelbaum FR; Morrison VA; Kolitz JE; Shepherd L; Hines JD; Schiffer CA; Larson RA
Blood; 2005 Jan; 105(1):49-53. PubMed ID: 15138165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
